Literature DB >> 15763344

Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.

Núria Guañabens1, Albert Parés, Inmaculada Ros, Llorenç Caballería, Francesca Pons, Sergi Vidal, Ana Monegal, Pilar Peris, Juan Rodés.   

Abstract

BACKGROUND: Since primary biliary cirrhosis (PBC) is usually diagnosed in postmenopausal women with minor cholestasis, it has been questioned whether PBC itself represents a further risk for osteoporosis. AIM: To assess the prevalence and risk factors for osteoporosis in an unselected series of women with PBC. PATIENTS AND METHODS: 142 women with PBC (age: 54.3+/-0.8 years) and an age-matched control group. Osteoporosis was established by densitometry (bone mineral density below -2.5 T-score). Age, duration and severity of PBC, body mass index, menopausal status, histological stage and markers of bone turnover were assessed.
RESULTS: Prevalence of osteoporosis was higher in PBC (32.4%) than in normal women (11. 1%) (RR: 3.83, 95%CI: 2.59-5.67, P<0.001). Osteoporosis was associated with older age, menopausal status, body mass index, longer PBC duration, advanced histological stage, high bilirubin and alkaline phosphatase, and low albumin and prothrombin index. Regression analysis identified older age, higher Mayo risk score, lower body mass index and advanced histological stage but not menopause as the independent risk factors for osteoporosis.
CONCLUSIONS: Osteoporosis is more prevalent in women with PBC than in the general population. Age and severity of the disease, but not menopausal status, are the main risk factors for osteoporosis in this liver disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763344     DOI: 10.1016/j.jhep.2004.11.035

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

2.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  Hepatobiliary Quiz Answers - 18 (2016).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-07-25

Review 4.  Osteodystrophy in chronic liver diseases.

Authors:  Pasquale Mansueto; Antonio Carroccio; Aurelio Seidita; Gaetana Di Fede; Antonio Craxì
Journal:  Intern Emerg Med       Date:  2012-01-13       Impact factor: 3.397

Review 5.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

6.  Association between primary biliary cholangitis and osteoporosis: meta-analysis.

Authors:  Junyu Fan; Qian Wang; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2017-09-26       Impact factor: 2.980

7.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 8.  Classical and emerging roles of vitamin D in hepatitis C virus infection.

Authors:  Julio A Gutierrez; Neil Parikh; Andrea D Branch
Journal:  Semin Liver Dis       Date:  2011-12-21       Impact factor: 6.115

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 10.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.